270
Participants
Start Date
November 30, 2010
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
Ataluren
Ataluren will be administered as per the dose and schedule specified in the arm.
Columbia University Pediatric Neuromuscular Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of the King's Daughters, Norfolk
Duke University Medical Center, Durham
Rare Disease Research, LLC, Atlanta
Child Neurology Center of NW Florida NW, Gulf Breeze
Nationwide Children's Hospital, Columbus
Cincinnati Childrens Hospital Medical Center, Cincinnati
University of Michigan, Ann Arbor
University of Iowa Children's Hospital, Iowa City
University of Minnesota, Minneapolis
Rush Univ Medical Center, Chicago
Washington University Medical School, St Louis
University of Kansas Medical Center, Kansas City
Childrens Medical Center Dallas, Dallas
Texas Children's Hospital, Houston
University of Texas Health Science Center at San Antonio, San Antonio
Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora
University of Utah, Salt Lake City
Phoenix Childrens Hospital, Phoenix
Children's Hospital of Los Angeles, Los Angeles
UCLA, Los Angeles
University of CA, San Francisco-Benioff Children's Hospital, San Francisco
Stanford University, Palo Alto
University of California-Davis, Sacramento
Shriners Hospital for Children-Portland, Portland
Seattle Children's Hospital, Seattle
Children's Hospital of Boston/Harvard Medical School, Boston
Alberta Children's Hospital, Calgary
British Columbia Children's Hospital, Vancouver
London Health Sciences Centre, London
Children's Hospital of East Ontario, Ottawa
CHU de Québec - Université Laval, Québec
Lead Sponsor
PTC Therapeutics
INDUSTRY